Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning. / Korfage, Ida J; Polinder, Suzanne; Preston, Nancy; van Delden, Johannes Jm; Geraerds, Sandra A Jlm; Dunleavy, Lesley; Faes, Kristof; Miccinesi, Guido; Carreras, Giulia; Moeller Arnfeldt, Caroline; Kars, Marijke C; Lippi, Giuseppe; Lunder, Urska; Mateus, Ceu; Pollock, Kristian; Deliens, Luc; Groenvold, Mogens; van der Heide, Agnes; Rietjens, Judith Ac.

In: Palliative Medicine, Vol. 37, No. 5, 05.2023, p. 707-718.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Korfage, IJ, Polinder, S, Preston, N, van Delden, JJ, Geraerds, SAJ, Dunleavy, L, Faes, K, Miccinesi, G, Carreras, G, Moeller Arnfeldt, C, Kars, MC, Lippi, G, Lunder, U, Mateus, C, Pollock, K, Deliens, L, Groenvold, M, van der Heide, A & Rietjens, JA 2023, 'Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning', Palliative Medicine, vol. 37, no. 5, pp. 707-718. https://doi.org/10.1177/02692163221142950

APA

Korfage, I. J., Polinder, S., Preston, N., van Delden, J. J., Geraerds, S. A. J., Dunleavy, L., Faes, K., Miccinesi, G., Carreras, G., Moeller Arnfeldt, C., Kars, M. C., Lippi, G., Lunder, U., Mateus, C., Pollock, K., Deliens, L., Groenvold, M., van der Heide, A., & Rietjens, J. A. (2023). Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning. Palliative Medicine, 37(5), 707-718. https://doi.org/10.1177/02692163221142950

Vancouver

Korfage IJ, Polinder S, Preston N, van Delden JJ, Geraerds SAJ, Dunleavy L et al. Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning. Palliative Medicine. 2023 May;37(5):707-718. https://doi.org/10.1177/02692163221142950

Author

Korfage, Ida J ; Polinder, Suzanne ; Preston, Nancy ; van Delden, Johannes Jm ; Geraerds, Sandra A Jlm ; Dunleavy, Lesley ; Faes, Kristof ; Miccinesi, Guido ; Carreras, Giulia ; Moeller Arnfeldt, Caroline ; Kars, Marijke C ; Lippi, Giuseppe ; Lunder, Urska ; Mateus, Ceu ; Pollock, Kristian ; Deliens, Luc ; Groenvold, Mogens ; van der Heide, Agnes ; Rietjens, Judith Ac. / Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning. In: Palliative Medicine. 2023 ; Vol. 37, No. 5. pp. 707-718.

Bibtex

@article{7846ddcf5f794851846648b4e1566fe2,

title = "Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning",

abstract = "BACKGROUND: Advance care planning supports patients to reflect on and discuss preferences for future treatment and care. Studies of the impact of advance care planning on healthcare use and healthcare costs are scarce.AIM: To determine the impact on healthcare use and costs of an advance care planning intervention across six European countries.DESIGN: Cluster-randomised trial, registered as ISRCTN63110516, of advance care planning conversations supported by certified facilitators.SETTING/PARTICIPANTS: Patients with advanced lung or colorectal cancer from 23 hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the UK. Data on healthcare use were collected from hospital medical files during 12 months after inclusion.RESULTS: Patients with a good performance status were underrepresented in the intervention group (p< 0.001). Intervention and control patients spent on average 9 versus 8 days in hospital (p = 0.07) and the average number of X-rays was 1.9 in both groups. Fewer intervention than control patients received systemic cancer treatment; 79% versus 89%, respectively (p< 0.001). Total average costs of hospital care during 12 months follow-up were €32,700 for intervention versus €40,700 for control patients (p = 0.04 with bootstrap analyses). Multivariable multilevel models showed that lower average costs of care in the intervention group related to differences between study groups in country, religion and WHO-status. No effect of the intervention on differences in costs between study groups was observed (p = 0.3).CONCLUSIONS: Lower care costs as observed in the intervention group were mainly related to patients' characteristics. A definite impact of the intervention itself could not be established.",

author = "Korfage, {Ida J} and Suzanne Polinder and Nancy Preston and {van Delden}, {Johannes Jm} and Geraerds, {Sandra A Jlm} and Lesley Dunleavy and Kristof Faes and Guido Miccinesi and Giulia Carreras and {Moeller Arnfeldt}, Caroline and Kars, {Marijke C} and Giuseppe Lippi and Urska Lunder and Ceu Mateus and Kristian Pollock and Luc Deliens and Mogens Groenvold and {van der Heide}, Agnes and Rietjens, {Judith Ac}",

year = "2023",

month = may,

doi = "10.1177/02692163221142950",

language = "English",

volume = "37",

pages = "707--718",

journal = "Palliative Medicine",

issn = "0269-2163",

publisher = "SAGE Publications",

number = "5",

}

RIS

TY - JOUR

T1 - Healthcare use and healthcare costs for patients with advanced cancer; the international ACTION cluster-randomised trial on advance care planning

AU - Korfage, Ida J

AU - Polinder, Suzanne

AU - Preston, Nancy

AU - van Delden, Johannes Jm

AU - Geraerds, Sandra A Jlm

AU - Dunleavy, Lesley

AU - Faes, Kristof

AU - Miccinesi, Guido

AU - Carreras, Giulia

AU - Moeller Arnfeldt, Caroline

AU - Kars, Marijke C

AU - Lippi, Giuseppe

AU - Lunder, Urska

AU - Mateus, Ceu

AU - Pollock, Kristian

AU - Deliens, Luc

AU - Groenvold, Mogens

AU - van der Heide, Agnes

AU - Rietjens, Judith Ac

PY - 2023/5

Y1 - 2023/5

N2 - BACKGROUND: Advance care planning supports patients to reflect on and discuss preferences for future treatment and care. Studies of the impact of advance care planning on healthcare use and healthcare costs are scarce.AIM: To determine the impact on healthcare use and costs of an advance care planning intervention across six European countries.DESIGN: Cluster-randomised trial, registered as ISRCTN63110516, of advance care planning conversations supported by certified facilitators.SETTING/PARTICIPANTS: Patients with advanced lung or colorectal cancer from 23 hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the UK. Data on healthcare use were collected from hospital medical files during 12 months after inclusion.RESULTS: Patients with a good performance status were underrepresented in the intervention group (p< 0.001). Intervention and control patients spent on average 9 versus 8 days in hospital (p = 0.07) and the average number of X-rays was 1.9 in both groups. Fewer intervention than control patients received systemic cancer treatment; 79% versus 89%, respectively (p< 0.001). Total average costs of hospital care during 12 months follow-up were €32,700 for intervention versus €40,700 for control patients (p = 0.04 with bootstrap analyses). Multivariable multilevel models showed that lower average costs of care in the intervention group related to differences between study groups in country, religion and WHO-status. No effect of the intervention on differences in costs between study groups was observed (p = 0.3).CONCLUSIONS: Lower care costs as observed in the intervention group were mainly related to patients' characteristics. A definite impact of the intervention itself could not be established.

AB - BACKGROUND: Advance care planning supports patients to reflect on and discuss preferences for future treatment and care. Studies of the impact of advance care planning on healthcare use and healthcare costs are scarce.AIM: To determine the impact on healthcare use and costs of an advance care planning intervention across six European countries.DESIGN: Cluster-randomised trial, registered as ISRCTN63110516, of advance care planning conversations supported by certified facilitators.SETTING/PARTICIPANTS: Patients with advanced lung or colorectal cancer from 23 hospitals in Belgium, Denmark, Italy, the Netherlands, Slovenia and the UK. Data on healthcare use were collected from hospital medical files during 12 months after inclusion.RESULTS: Patients with a good performance status were underrepresented in the intervention group (p< 0.001). Intervention and control patients spent on average 9 versus 8 days in hospital (p = 0.07) and the average number of X-rays was 1.9 in both groups. Fewer intervention than control patients received systemic cancer treatment; 79% versus 89%, respectively (p< 0.001). Total average costs of hospital care during 12 months follow-up were €32,700 for intervention versus €40,700 for control patients (p = 0.04 with bootstrap analyses). Multivariable multilevel models showed that lower average costs of care in the intervention group related to differences between study groups in country, religion and WHO-status. No effect of the intervention on differences in costs between study groups was observed (p = 0.3).CONCLUSIONS: Lower care costs as observed in the intervention group were mainly related to patients' characteristics. A definite impact of the intervention itself could not be established.

U2 - 10.1177/02692163221142950

DO - 10.1177/02692163221142950

M3 - Journal article

C2 - 36515362

VL - 37

SP - 707

EP - 718

JO - Palliative Medicine

JF - Palliative Medicine

SN - 0269-2163

IS - 5

ER -

ID: 328901194